Protuoso Bio

Protuoso Bio is engaged in the development of sophisticated protein architectures to tackle complex diseases. The company is headquartered in San Carlos, US.Protuoso Biosciences primarily focuses on the development of MUXBODIES™, which are sophisticated multifunctional protein architectures engineered through advanced AI-driven protein engineering and synthetic biology. These products are designed to address complex diseases that currently lack effective therapeutic options, integrating precision design with scalable innovation to enhance efficacy and safety. The MUXBODIES™ are part of a broader therapeutic portfolio targeting areas such as advanced cardiometabolic disease and armored immune cell engagement. The company’s innovative hub-and-spoke model enables it to efficiently develop multiple therapeutic assets simultaneously, allowing for parallel innovation and effective resource allocation.Protuoso Biosciences engages in revenue generation through partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare organizations. The company’s business transactions revolve around the licensing of its proprietary MUXBODIES™ technology and collaborative agreements for product development. These partnerships may involve upfront payments, milestone-based payments tied to development progress, and royalties on future sales of developed therapeutics. The transactional framework emphasizes value-sharing based on the therapeutic efficacy and market potential of the MUXBODIES™, creating a diversified revenue stream anchored in its innovative platform.

1. Seed

   May 27, 2026

   Amount

   $9.5M

   Investors

   Locked